Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

na

SHINGRIX is formulated to help protect against shingles.1,2

SHINGRIX is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:

  • adults 50 years of age or older; 
  • adults 18 years of age or older at increased risk of HZ.1,2

It is the first and only non-live shingles vaccine, and the vaccination schedule consists of 2-doses1,2

na

Explore SHINGRIX Efficacy data

VIEW SHINGRIX Safety data

Learn more about how SHINGRIX works

SHINGRIX is specifically formulated to address the age related decline in shingles immunity

SHINGRIX reconstitution instructions

Instructions for reconstituting and administering SHINGRIX to your patients

Use of SHINGRIX should be in accordance with official recommendations, and the Shingles National Immunisation Programme.

Check out our resources to support you with implementing the programme.

Explore tips & resources

Prescribing Information (GB & NI)

Download

Summary of product characteristics & Patient information leaflet (GB)

open

Summary of product characteristics & Patient information leaflet (NI)

open

References

  1. SHINGRIX. Summary of Product Characteristics (GB)
  2. SHINGRIX, Northern Ireland Summary of Product Characteristics (SPC)
  3. The GreenBook chapter 28a – Shingles. March 2024

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441 or UKSafety@gsk.com.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2024 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

December 2024 | PM-GB-SGX-WCNT-230008 (V3.0)